Ehong Gu - Dec 19, 2023 Form 3 Insider Report for LianBio (LIAN)

Role
Interim CFO
Signature
/s/ Brianne Jahn, Attorney-in-Fact
Stock symbol
LIAN
Transactions as of
Dec 19, 2023
Transactions value $
$0
Form type
3
Date filed
12/26/2023, 04:10 PM
Next filing
Apr 11, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding LIAN Ordinary Shares 78.5K Dec 19, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding LIAN Stock Option (Right to Buy) Dec 19, 2023 Ordinary Shares 117K $16.00 Direct F2
holding LIAN Stock Option (Right to Buy) Dec 19, 2023 Ordinary Shares 54.6K $2.66 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents (i) 9,351 Ordinary Shares, (ii) 30,809 restricted share units ("RSUs") remaining out of the 41,078 RSUs granted to the Reporting Person under the LianBio 2021 Equity Incentive Plan on December 31, 2021, 25% of which vested on December 31, 2022 and the remainder of which shall vest in 25% annual installments such that the RSUs are fully vested on December 31, 2025, subject to the Reporting Person providing continuous service to the Issuer on each such date, and (iii) 38,333 RSUs granted to the Reporting Person under the LianBio 2021 Equity Incentive Plan on March 29, 2023, 25% of which shall vest on March 29, 2024 and the remainder of which shall vest in 25% annual installments such that the RSUs are fully vested on March 29, 2027, subject to the Reporting Person providing continuous service to the Issuer on each such date. Each RSU represents the contingent right to receive one share of the Issuer's Ordinary Shares.
F2 25% of the shares underlying the option vested and became exercisable on the first anniversary of the commencement date, October 31, 2022; the remainder shall vest and become exercisable in 36 equal monthly installments such that the option shall be fully vested on October 31, 2025, subject to the Reporting Person providing continuous service to the Issuer on each such date.
F3 25% of the shares underlying the option shall vest and become exercisable on the first anniversary of the commencement date, January 20, 2024; the remainder shall vest and become exercisable in 36 equal monthly installments such that the option shall be fully vested on January 20, 2027, subject to the Reporting Person providing continuous service to the Issuer on each such date.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney